Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study

被引:9
|
作者
Prosberg, Michelle V. [1 ]
Vester-Andersen, Marianne K. [1 ]
Andersson, Mikael [2 ]
Jess, Tine [2 ]
Andersen, Jon T. [3 ]
Vind, Ida [1 ]
Bendtsen, Flemming [1 ]
机构
[1] Univ Copenhagen, Hvidovre Hosp, Gastrounit, Med Sect, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark
[2] Natl Hlth Surveillance & Res, Dept Epidemiol Res, Copenhagen, Denmark
[3] Rigshosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark
关键词
ulcerative colitis; compliance; recurrence; INFLAMMATORY-BOWEL-DISEASE; MEDICATION NONADHERENCE; SURGERY RATES; MESALAZINE; MESALAMINE; ADHERENCE; DIAGNOSIS; PERSISTENCE; PREDICTORS; PHENOTYPE;
D O I
10.1097/MIB.0000000000000700
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Noncompliance to long-term medical therapy is a well-known problem among patients treated for ulcerative colitis, but studies of long-term consequences in unselected patients are lacking. The authors aimed to determine the risk of recurrence according to long-term compliance with oral 5-aminosalicylic acid among unselected patients with ulcerative colitis. Methods: The authors conducted a 7-year follow-up study of a population-based inception cohort of 243 Danish patients with ulcerative colitis diagnosed from 2003 to 2004. Compliance was defined as consumption of >= 80% of prescribed oral 5-aminosalicylic acid. Data were collected from medical records and the Danish National Prescription Database. They performed Cox regression analysis with adjustments for demographic and clinical characteristics to examine risk of recurrence (defined by increased use of oral 5-Aminosalicylic Acid, other additional treatment, or colectomy) in compliant versus noncompliant patients. Results: In total, 182 patients (75%) experienced at least 1 recurrence during follow-up. For the first year after diagnosis, risk of recurrence did not differ significantly between compliant and noncompliant patients. For 1 to 3 years (hazard ratio: 0.46, 95% CI, 0.33-0.63) and 3 to 8 years (hazard ratio: 0.42, 95% CI, 0.32-0.55) after diagnosis, risk of recurrence was significantly decreased among noncompliant patients compared with that of compliant patients. Conclusions: This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis. This is unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Results may instead reflect that patients during recurrence-free periods through self-management choose not to take their medication.
引用
收藏
页码:925 / 932
页数:8
相关论文
共 50 条
  • [21] Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
    Park, Soo-Kyung
    Kang, Sang-Bum
    Kim, SangSoo
    Kim, Tae Oh
    Cha, Jae Myung
    Im, Jong Pil
    Choi, Chang Hwan
    Kim, Eun Soo
    Seo, Geom Seog
    Eun, Chang Soo
    Han, Dong Soo
    Park, Dong Il
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2022, 37 (05): : 949 - +
  • [22] COATED ORAL 5-AMINOSALICYLIC ACID THERAPY FOR MILDLY TO MODERATELY ACTIVE ULCERATIVE-COLITIS - A RANDOMIZED STUDY
    SCHROEDER, KW
    TREMAINE, WJ
    ILSTRUP, DM
    NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (26): : 1625 - 1629
  • [23] Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects
    Di Paolo, MC
    Paoluzi, OA
    Pica, R
    Iacopini, F
    Crispino, P
    Rivera, M
    Spera, G
    Paoluzi, P
    DIGESTIVE AND LIVER DISEASE, 2001, 33 (07) : 563 - 569
  • [24] LONG-TERM ORAL-THERAPY OF CHRONIC INFLAMMATORY INTESTINAL DISEASE WITH 5-AMINOSALICYLIC ACID (CLAVERSAL, SALOFALK)
    MAIER, K
    VANDERGAISBERG, U
    KLOTZ, U
    WIENER KLINISCHE WOCHENSCHRIFT, 1986, 98 (16) : 557 - 557
  • [25] Acute pancreatitis after long-term 5-aminosalicylic acid therapy
    Fernandez, J
    Sala, M
    Panes, J
    Feu, F
    Navarro, S
    Teres, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1997, 92 (12): : 2302 - 2303
  • [26] Natural History and Predictors of Treatment Failure in Patients With Ulcerative Colitis on 5-Aminosalicylic Acid: A US Population-Level Cohort Study
    Kochhar, Gursimran S.
    Khataniar, Himsikhar
    Hashash, Jana G.
    Farraye, Francis A.
    Desai, Aakash
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S783 - S784
  • [27] No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study
    Mak, Joyce W. Y.
    Yuen, Nobel T. K.
    Yip, Terry C. F.
    Lam, Ray H. M.
    Lam, Brian K. H.
    Cheng, Cherry T. Y.
    Wong, Grace L. H.
    Chan, Francis K. L.
    Ng, Siew C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (07) : 1284 - 1289
  • [28] Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs
    Debanjali, M.
    Hodgkins, P.
    Yen, L.
    Solomon, D.
    Davis, K.
    Cohen, R.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S32 - S32
  • [29] The real-world practice patterns and clinical outcomes of 5-aminosalicylic acid treatment in Korean patients with ulcerative colitis: a population-based retrospective study
    Park, S. J.
    Park, S. W.
    Kim, T., I
    Cheon, J. H.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1446 - i1446
  • [30] COMPARING ORAL 5-AMINOSALICYLIC ACID TREATMENT PERSISTENCE AND ADHERENCE IN PATIENTS WITH ULCERATIVE COLITIS IN THE UNITED STATES
    Yen, L.
    Wu, J.
    Hodgkins, P.
    Nichol, M. B.
    VALUE IN HEALTH, 2012, 15 (07) : A615 - A616